RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Osteosarcoma (bone cancer) has poor clinical outcomes, necessitating novel therapeutic strategies.
• Immunotherapy has transformed solid tumor treatment, highlighting the need for new immunotherapy targets in osteosarcoma.

Purpose of the Study:

• To investigate the link between RNA modifications and immunotherapy in osteosarcoma.
• To identify novel therapeutic targets for osteosarcoma by analyzing RNA modification-related signatures.

Main Methods:

• Developed an RNA modification-related signature using weighted gene correlation network analysis and random forest machine learning.
• Analyzed the signature's prognostic value, drug prediction capabilities, and immune characteristics.
• Identified EIF4G2 as a critical immunotherapy determinant using single-cell sequencing and in vitro validation.

Main Results:

• An RNA modification-related signature was successfully established for osteosarcoma.
• EIF4G2 was identified as a key factor influencing immunotherapy response in osteosarcoma.
• EIF4G2 was found to promote tumor proliferation, migration, and M2 macrophage infiltration.

Conclusions:

• The developed signature and EIF4G2 represent promising therapeutic targets for osteosarcoma.
• These findings offer valuable insights for advancing osteosarcoma clinical management through immunotherapy.